Mersana Therapeutics

• The FDA has granted Fast Track designation to Mersana's Emiltatug Ledadotin (XMT-1660) for advanced or metastatic HER2-low or HER2-negative breast cancer, including triple-negative breast cancer. • This designation applies to patients who have previously received a topoisomerase-1 inhibitor ADC and, if hormone-receptor positive, have received or are ineligible for endocrine therapy. • Phase 1 trial data shows Emiltatug Ledadotin demonstrates promising efficacy and a favorable safety profile, particularly in heavily pre-treated triple-negative breast cancer patients. • The WHO has approved emiltatug ledadotin (Emi-Le) as the international nonproprietary name (INN) for XMT-1660, marking a significant step in its global recognition.

Mersana Therapeutics' Emiltatug Ledadotin (XMT-1660) demonstrates a favorable safety profile in a Phase 1 trial with no Grade 4 or 5 treatment-related adverse events.

Merus' petosemtamab demonstrates a 36% overall response rate in recurrent/metastatic head and neck squamous cell carcinoma, with median overall survival of 11.4 months.